MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma
Status:
Completed
Trial end date:
2011-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in
the treatment of participants with platinum-refractory or platinum-resistant epithelial
ovarian, fallopian tube, or primary peritoneal carcinomas.